Identification

Name
Dihydroergocristine
Accession Number
DB13345
Type
Small Molecule
Groups
Approved, Experimental
Description

Dihydroergocristine is part of the ergoloid mixture products.[7] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.[1] To know more about ergoloid mixtures, please visit Ergoloid mesylate.

Structure
Thumb
Synonyms
  • 9,10-dihydroergocristine
  • DHEC
Product Ingredients
IngredientUNIICASInChI Key
Dihydroergocristine mesylateDS7CL18UAM24730-10-7SPXACGZWWVIDGR-SPZWACKZSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralCarilion Materials Management1991-10-31Not applicableUs
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralSun Pharmaceutical Industries Limited1991-10-31Not applicableUs
International/Other Brands
Iskevert (Medley S/A)
Categories
UNII
05D48LUM4Z
CAS number
17479-19-5
Weight
Average: 611.743
Monoisotopic: 611.31076944
Chemical Formula
C35H41N5O5
InChI Key
DEQITUUQPICUMR-HJPBWRTMSA-N
InChI
InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboximidic acid
SMILES
[H][C@@]12CCCN1C(=O)[C@]([H])(CC1=CC=CC=C1)N1C(=O)[C@@](O[C@@]21O)(N=C(O)[C@@]1([H])CN(C)[C@]2([H])CC3=CNC4=CC=CC(=C34)[C@@]2([H])C1)C(C)C

Pharmacology

Indication

Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.[8] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Pharmacodynamics

Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states.[2] The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation.[8] It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals.[1] This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles.[8] The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine.[2] In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types.[4] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Mechanism of action

Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors.[2] In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.[4]

TargetActionsOrganism
ASerotonin Receptors
antagonist
Human
ABeta adrenergic receptor
antagonist
agonist
Human
AAlpha adrenergic receptor
antagonist
agonist
Human
ADopamine receptor
antagonist
agonist
Human
Absorption

Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h.[3] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Volume of distribution

Dihydroergocristine presents a large volume of distribution of 52 l/kg.[6] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Protein binding

Dihydroergocristine can be found in a bound state to plasma proteins in a proportion of even 68% of the administered dose.[3] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Metabolism

The major metabolite of dihydroergocristine is 8'-hydroxy-dihydroergocristine is produced in the liver.[3] The modification of dihydroergocristine in the body is very extensive and it has been observed as an almost complete absence of the unchanged drug.[6] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Route of elimination

The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose.[5] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Half life

The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to Ergoloid mesylate.

Clearance

Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg.[6] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Toxicity

Studies related to acute and chronic toxicity as well as teratogenesis and fertility has proven that dihydroergocristine is a non-toxic and very well tolerated drug.[2] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineDihydroergocristine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
AcetaminophenThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Aldesleukin.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Alprazolam.Approved, Illicit, Investigational
AmbroxolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ambroxol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Amlodipine.Approved
AmprenavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Amprenavir.Approved, Investigational
AnastrozoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Anastrozole.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Antipyrine.Approved, Investigational
ApraclonidineDihydroergocristine may increase the hypertensive activities of Apraclonidine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atorvastatin.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Azelastine.Approved
AzithromycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Azithromycin.Approved
BenzphetamineDihydroergocristine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BetamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Betamethasone.Approved, Vet Approved
BicalutamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bicalutamide.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bifonazole.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bortezomib.Approved, Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Brentuximab vedotin.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cabergoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Caffeine.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Capsaicin.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Caspofungin.Approved
CeritinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ceritinib.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cerivastatin.Approved, Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Chlorzoxazone.Approved
CilostazolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cilostazol.Approved, Investigational
Cimicifuga racemosaThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cimicifuga racemosa.Approved, Experimental
CiprofloxacinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ciprofloxacin.Approved, Investigational
CirazolineDihydroergocristine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clemastine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clomifene.Approved, Investigational
ClonidineDihydroergocristine may increase the hypertensive activities of Clonidine.Approved
ClotiazepamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clozapine.Approved
CobicistatThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cocaine.Approved, Illicit
ColchicineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Colchicine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Curcumin.Approved, Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cyclosporine.Approved, Investigational, Vet Approved
DalfopristinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Danazol.Approved
DarunavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Darunavir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Daunorubicin.Approved
DelavirdineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Desipramine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dihydroergotamine.Approved, Investigational
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DipivefrinDihydroergocristine may increase the hypertensive activities of Dipivefrin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dronedarone.Approved
DroxidopaDihydroergocristine may increase the hypertensive activities of Droxidopa.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Econazole.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Efonidipine.Approved, Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Elbasvir.Approved
EnasidenibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Enasidenib.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Epinephrine.Approved, Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ergotamine.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Erythromycin.Approved, Investigational, Vet Approved
EthanolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ethanol.Approved
EtoposideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Etoricoxib.Approved, Investigational
EzetimibeThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ezetimibe.Approved
FelodipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Felodipine.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluticasone propionate.Approved
FluvastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fosamprenavir.Approved
FosaprepitantThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fosaprepitant.Approved
FosnetupitantThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fosnetupitant.Approved
GemfibrozilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Gemfibrozil.Approved
GlyburideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Haloperidol.Approved
HistamineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Histamine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Imatinib.Approved
IndinavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Indinavir.Approved
IndisulamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Indisulam.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Isavuconazonium.Approved, Investigational
IsomethepteneDihydroergocristine may increase the hypertensive activities of Isometheptene.Approved
IsoniazidThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Isoniazid.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Isradipine.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Itraconazole.Approved, Investigational
IvacaftorThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ivacaftor.Approved
JosamycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Josamycin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ketazolam.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Linagliptin.Approved
LofexidineDihydroergocristine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lomustine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Loratadine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Losartan.Approved
LovastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lovastatin.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Luliconazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lurasidone.Approved, Investigational
ManidipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Manidipine.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mefloquine.Approved, Investigational
MephentermineDihydroergocristine may increase the hypertensive activities of Mephentermine.Approved
MequitazineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mequitazine.Approved
MetaraminolDihydroergocristine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methimazole.Approved
MethoxamineDihydroergocristine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methylergometrine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Metyrapone.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Midazolam.Approved, Illicit
MidodrineDihydroergocristine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mifepristone.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mirtazapine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mitoxantrone.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Modafinil.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nabilone.Approved, Investigational
NaphazolineDihydroergocristine may increase the hypertensive activities of Naphazoline.Approved
NelfinavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nelfinavir.Approved
NetupitantThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Netupitant.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nicardipine.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nicotinamide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nifedipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nilvadipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitric Oxide.Approved
NitroglycerinThe bioavailability of Dihydroergocristine can be increased when combined with Nitroglycerin.Approved, Investigational
NorepinephrineDihydroergocristine may increase the hypertensive activities of Norepinephrine.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Norfloxacin.Approved
NoscapineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Noscapine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Olanzapine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Olaparib.Approved
OmeprazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Omeprazole.Approved, Investigational, Vet Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Oxetacaine.Approved, Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Oxybutynin.Approved, Investigational
OxymetazolineDihydroergocristine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymetholoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Palbociclib.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Paramethasone.Approved
PazopanibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pazopanib.Approved
Peppermint oilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Peppermint oil.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhendimetrazineDihydroergocristine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Phenelzine.Approved
PhenylephrineDihydroergocristine may increase the hypertensive activities of Phenylephrine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pilocarpine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pimozide.Approved
PiperaquineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Piperaquine.Approved, Investigational
PosaconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pravastatin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Prednisone.Approved, Vet Approved
PrimaquineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Primaquine.Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Progesterone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Propofol.Approved, Investigational, Vet Approved
PseudoephedrineDihydroergocristine may increase the hypertensive activities of Pseudoephedrine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rabeprazole.Approved, Investigational
RacepinephrineDihydroergocristine may increase the hypertensive activities of Racepinephrine.Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Raloxifene.Approved, Investigational
RanitidineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ranitidine.Approved
RanolazineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ranolazine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Regorafenib.Approved
RepaglinideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Repaglinide.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Resveratrol.Approved, Experimental, Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Risperidone.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rivastigmine.Approved, Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rolitetracycline.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rucaparib.Approved, Investigational
RutinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rutin.Experimental, Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sarilumab.Approved, Investigational
SertralineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sertraline.Approved
SildenafilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sildenafil.Approved, Investigational
SimeprevirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Simvastatin.Approved
SirolimusThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sirolimus.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sorafenib.Approved, Investigational
StiripentolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tadalafil.Approved, Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tamoxifen.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Teniposide.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Testosterone cypionate.Approved
Testosterone enanthateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tetracycline.Approved, Vet Approved
TetryzolineDihydroergocristine may increase the hypertensive activities of Tetryzoline.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Thiopental.Approved, Vet Approved
TicagrelorThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ticlopidine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tioconazole.Approved
TipranavirThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tipranavir.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tofisopam.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Topiroxostat.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Topotecan.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tranylcypromine.Approved, Investigational
TroglitazoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Troleandomycin.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Venlafaxine.Approved
VinblastineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vincristine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Voriconazole.Approved, Investigational
XylometazolineDihydroergocristine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZafirlukastThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ziprasidone.Approved
ZucapsaicinThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Drago F, Valerio C, Scalisi B, D'Agata V, Scapagnini U: Dihydroergocristine and memory alterations of aged male rats. Pharmacol Biochem Behav. 1988 Aug;30(4):961-5. [PubMed:3147464]
  2. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
  3. Bicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello A, Luciano P, Santagada V, Pereira AS, De Nucci G: Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. Curr Drug Metab. 2005 Dec;6(6):519-29. [PubMed:16379666]
  4. Lei X, Yu J, Niu Q, Liu J, Fraering PC, Wu F: The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-beta peptides. Sci Rep. 2015 Nov 16;5:16541. doi: 10.1038/srep16541. [PubMed:26567970]
  5. Nimmerfall F, Rosenthaler J: Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J Pharmacokinet Biopharm. 1976 Feb;4(1):57-66. [PubMed:1271240]
  6. Grognet JM, Riviere R, Istin M, Zanotti A, Coppi G: [The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. Arzneimittelforschung. 1992 Nov;42(11A):1394-6. [PubMed:1492859]
  7. Dailymed [Link]
  8. ANVISA [Link]
External Links
KEGG Drug
D07834
ChemSpider
96884
BindingDB
50390992
ChEBI
59912
ChEMBL
CHEMBL601773
Wikipedia
Dihydroergocristine
ATC Codes
C04AE04 — DihydroergocristineC04AE54 — Dihydroergocristine, combinations
MSDS
Download (76.2 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)213-215 ºC'MSDS'
boiling point (°C)899.3 ºC at 760 mm HgProduct specifications
water solubility10 mg/ml'MSDS'
logP5.86Buckingham J. et al. Dictionary of Alkaloids.
pKa6.9Lemke T. and Williams D. Foye's Principles of Medicinal Chemistry.
Predicted Properties
PropertyValueSource
Water Solubility0.0492 mg/mLALOGPS
logP3.58ALOGPS
logP2.16ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.75ChemAxon
pKa (Strongest Basic)8.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area121.7 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity168.8 m3·mol-1ChemAxon
Polarizability67.82 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Isoindoles and derivatives / Piperidinecarboxamides / Aralkylamines / N-alkylpiperazines / Benzene and substituted derivatives
show 17 more
Substituents
Lysergic acid amide / Indoloquinoline / Benzoquinoline / N-acyl-alpha amino acid or derivatives / Pyrroloquinoline / Alpha-amino acid or derivatives / Quinoline / 3-alkylindole / Indole / Indole or derivatives
show 41 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
ergot alkaloid (CHEBI:59912)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]

Drug created on June 23, 2017 14:40 / Updated on July 02, 2018 21:01